Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
160 Leser
Artikel bewerten:
(0)

Global Strategic Business Radiopharmaceuticals Report 2013-2018: High Costs of Drug Development Piques Manufacturers

DUBLIN, Ireland, October 21, 2013 /PRNewswire/ --

Research and Markets
( http://www.researchandmarkets.com/research/ssfwwf/radiopharmaceutica) has announced the addition of the "Radiopharmaceuticals - Global Strategic Business Report" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments:

  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals.

The report profiles 69 companies including many key and niche players such as:

  • Actinium Pharmaceuticals Inc.
  • Advanced Medical Isotope Corporation
  • Alseres Pharmaceuticals Inc.
  • Bayer HealthCare Pharmaceuticals
  • Bracco Diagnostics Inc.
  • Cardinal Health Inc.
  • Covidien Plc
  • Eli Lilly and Company
  • Erigal Limited
  • EUSA Pharma (Europe) Ltd.
  • GE Healthcare
  • IBA Group
  • Immunomedics Inc.
  • Jubilant Life Sciences Limited
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd.
  • Nordion Inc.
  • Peregrine Pharmaceuticals Inc.
  • PETNET Solutions Inc.
  • Positron Corporation
  • Singapore Radiopharmaceuticals Pte Ltd.
  • Triad Isotopes Inc.

Key Topics Covered: Click the link below to view the full extended table of contents and list of companies featured.


I. Introduction, Methodology & Product Definitions

II. Executive Summary

1. Industry Overview

2. Growth Drivers & Trends

3. Market Challenges

4. Therapeutic Radiopharmaceutical Products Under Development

5. Imaging Agents - An Overview

6. Nuclear Medicine - An Overview

7. Product Overview

8. Product Innovations/Introductions

9. Product Innovations/Introductions In Recent Past- A Perspective Builder

10. Recent Industry Activity

11. Corporate Activity In The Recent Past - A Perspective Builder

12. Focus On Select Players

13. Global Market Perspective

III. Market

1. The United States

2. Canada

3. Japan

4. Europe

5. Asia-Pacific

6. Middle East

7. Latin America

IV. Competitive Landscape

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79)

  • The United States (36)
  • Canada (2)
  • Japan (1)
  • Europe (28)
  • - France (2)
  • - Germany (2)
  • - The United Kingdom (4)
  • - Italy (2)
  • - Spain (1)
  • - Rest of Europe (17)
  • Asia-Pacific (Excluding Japan) (9)
  • Latin America (1)
  • Africa (1)
  • Middle East (1)

For more information visit http://www.researchandmarkets.com/research/ssfwwf/radiopharmaceutica

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.